Aprotinin inhibits thrombin formation and monocyte tissue factor in simulated cardiopulmonary bypass

• Published in: The Annals of thoracic surgery Vol. 68; no. 2; pp. 473 - 478
• Main Authors: Khan, Mohammad M.H, Gikakis, Nicolas, Miyamoto, Shinji, Rao, A.Koneti, Cooper, Stuart L, Edmunds, L.Henry, Colman, Robert W
• Format: Journal Article Conference Proceeding
• Language: English
• Published: New York, NY Elsevier Inc 01.08.1999; Elsevier Science
• Subjects: Anesthesia; Anesthesia depending on type of surgery; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Antithrombin III - metabolism; Aprotinin - pharmacology; Biological and medical sciences; Cardiopulmonary Bypass; Factor VIIa - antagonists & inhibitors; Hemostatics - pharmacology; Humans; Macrophage-1 Antigen - metabolism; Medical sciences; Models, Cardiovascular; Monocytes - drug effects; Peptide Fragments - metabolism; Peptide Hydrolases - metabolism; Prothrombin - metabolism; Thoracic and cardiovascular surgery. Cardiopulmonary bypass; Thromboplastin - metabolism; Human origin; Pharmacologic test; Membrane oxygenator; Monocyte; Coagulation; Tissue factor; Exploration; Biosynthesis; Blood; Cardiopulmonary bypass; Thrombin(drug); Simulation; Aprotinin; Inhibition

Background. Aprotinin reduces perioperative bleeding after open heart surgery, primarily by inhibiting fibrinolysis. In addition, the drug has both procoagulant and anticoagulant effects that involve complex reactions of coagulation proteins and cells that are incompletely understood. This study tes...